title: Shunt-related abdominal metastases in an infant with medulloblastoma: long-term remission by systemic chemotherapy and surgery.
abstract: This is the first reported case of long remission of abdominal metastases spread through a ventriculo-peritoneal shunt in an infant diagnosed, four years ago, at age 1 year and 10 months, to have cerebral medulloblastoma. Two years later, while in second complete remission of his cerebral tumor, he showed abdominal metastases, successfully treated by platinum based chemotherapy and surgery. One year later, a second abdominal relapse and hepatic metastases were treated by doxorubicin administration and surgery. Since then the child remained in continuous complete remission. This unusual favorable outcome can be explained by an extreme responsiveness of the tumor, unprotected by the blood brain barrier, to systemic chemotherapy, particularly to doxorubicin administration. The need for careful surveillance of patients with ventriculo-peritoneal shunts is emphasized. Searching for new tools, such as entrapment of doxorubicin in liposomes, able to overcome the blood-brain barrier and to expose brain tumors to effective drugs, probably represents the best choice for future treatment strategies of CNS tumors.
authors.affiliation: Pediatric Oncology Unit of the University Federico II, Naples, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Fiorillo
authors.forename: G
authors.initials: G
authors.lastname: Maggi
authors.forename: A
authors.initials: A
authors.lastname: Martone
authors.forename: R
authors.initials: R
authors.lastname: Migliorati
authors.forename: R
authors.initials: R
authors.lastname: D'Amore
authors.forename: E
authors.initials: E
authors.lastname: Alfieri
authors.forename: N
authors.initials: N
authors.lastname: Greco
authors.forename: S
authors.initials: S
authors.lastname: Cirillo
authors.forename: I
authors.initials: I
authors.lastname: Marano
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002330:Carmustine / Q000008:administration & dosage; D002528:Cerebellar Neoplasms / Q000473:pathology* / Q000532:radiotherapy / Q000601:surgery; D003131:Combined Modality Therapy; D016371:Cranial Irradiation; D003399:Craniotomy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D006849:Hydrocephalus / Q000601:surgery / Q000628:therapy; D006918:Hydroxyurea / Q000008:administration & dosage; D007223:Infant; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D008279:Magnetic Resonance Imaging; D008297:Male; D008527:Medulloblastoma / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary* / Q000601:surgery; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D010386:Pelvic Neoplasms / Q000188:drug therapy / Q000601:surgery; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000556:secondary* / Q000601:surgery; D012074:Remission Induction; D017287:Ventriculoperitoneal Shunt / Q000009:adverse effects*
chemical_list: D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D016190:Carboplatin; D002330:Carmustine; D006918:Hydroxyurea